Next month, IDSA, the Food and Drug Administration (FDA), and the National Institute of Allergy and Infectious Diseases (NIAID) will hold a joint workshop to bring together key researchers, physicians, regulators, and government officials to discuss the science around antibacterial resistance and new antibacterial drug and related rapid diagnostics development. The free public workshop, to be held July 26-27 in Silver Spring, Md., will focus on four key areas:
- scale of the current antibacterial resistance problem
- science and mechanisms of bacterial resistance
- science of development of rapid diagnostics
- science of antibacterial drug development
A follow-up IDSA report is planned to capture workshop highlights, note research gaps and priorities, and make recommendations for future research in these critical areas. In April, IDSA called on Congress to substantially increase NIAID’s funding for antibacterial resistance and drug discovery and development research to $500 million to help address the public health threat posed by drug resistance. The Society also asked lawmakers to significantly increase FDA’s budget for its antimicrobial resistance and antibacterial drug review programs and to support FDA’s new regulatory science initiative, part of a recommended overall funding increase for the agency (see IDSA’s congressional testimony).
The workshop will be webcast online and may be viewed for free by pre-registering online. Videos of the workshop presentations will also be available for free on IDSA’s site following the workshop. For more information, including how to register and attend in person, please visit the Society’s website.
< Previous Article | Next Article >